Search clinical trials for: bafetinib

Total 233 results

Nanjing Yoko Biomedical Co., Ltd.

Unknown

A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor

Neoplasms

China
CytRx

Completed

Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

B-Cell Chronic Lymphocytic Leukemia

United States
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
Centre Leon Berard
Boehringer Ingelheim

Completed

Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck (BIBW2992ORL)

Head and Neck Squamous Cell Carcinoma

France
University of Chicago
National Cancer Institute (NCI)

Recruiting

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
Boehringer Ingelheim

Completed

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

Carcinoma, Non-Small-Cell Lung

Greece
Boehringer Ingelheim

Completed

Trial of Afatinib in Pediatric Tumours

Neuroectodermal Tumors | Rhabdomyosarcoma

United States, Spain, Canada, Germany, Italy, United Kingdom, Australia, Austria, Denmark, Faroe Islands, France, Netherlands
Boehringer Ingelheim

Completed

Long-term Observation PMS for Afatinib

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Approved for marketing

Afatinib Expanded Access Program

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
Boehringer Ingelheim

No longer available

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Solid Tumors
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Boehringer Ingelheim

Completed

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Boehringer Ingelheim

Terminated

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms

United States, Taiwan
CytRx

Completed

Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer (PROACT)

Hormone Refractory Prostate Cancer

United States
Universitätsklinikum Hamburg-Eppendorf
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Refractory Cancer

Germany
Qingdao Central Hospital

Recruiting

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

PFS

China
National University Hospital, Singapore

Not yet recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Medical University of South Carolina
Boehringer Ingelheim

Withdrawn

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
Hellenic Cooperative Oncology Group
Boehringer Ingelheim

Completed

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (A-GAPP)

Gastric Cancer | Gastroesophageal Junction Cancer

Greece
Yonsei University

Completed

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NSCLC
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence

Head and Neck Squamous Cell Carcinoma

United States
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Enrolling by invitation

BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) (BEAR)

Esophageal Squamous Cell Carcinoma (ESCC)

Taiwan
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
CytRx

Completed

Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia

United States, Israel, Germany
Shanghai Chest Hospital

Not yet recruiting

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NRG1-fused Non-small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Carcinoma, Non-Small-Cell Lung

United States, Spain, Taiwan, China, United Kingdom, Denmark, Canada, Korea, Republic of, Germany, Italy, Netherlands, Singapore, Austria, France, Portugal, Greece, India, Mexico, Hungary, Turkey, Argentina, Chile, Ireland
Boehringer Ingelheim

Completed

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

Carcinoma, Non-Small-Cell Lung

Spain, Israel, Italy, Austria, Czechia, Greece, Australia, Poland, Hungary, Portugal, Russian Federation
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim

Recruiting

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma

United States
Boehringer Ingelheim

Completed

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Squamous Non-small Cell Lung Cancer

United States
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
UNICANCER

Completed

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

France
Boehringer Ingelheim

Completed

ADAM-Afatinib Diarrhea Assessment and Management

Carcinoma, Non-Small-Cell Lung

United States
German Cancer Research Center
German Consortium for Translational Cancer Research

Completed

Afatinib in Advanced NRG1-Rearranged Malignancies

Metastatic and Locally Advanced NRG1-rearranged Malignancies

Germany
Boehringer Ingelheim

Completed

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Stomach Neoplasms | Breast Neoplasms

France
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Boehringer Ingelheim

Completed

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Breast Neoplasms

United States, United Kingdom
Yonsei University

Completed

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute; United States Department of Defense; Boehringer... and other collaborators

Completed

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Gastric Cancer | Esophageal Cancer

United States
Samsung Medical Center

Unknown

Afatinib Plus Nimotuzumb for NSCLC

NSCLC

Korea, Republic of
Yale University
Boehringer Ingelheim; National Comprehensive Cancer Network

Recruiting

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Squamous Cell Cancers of the Head and Neck

United States
National Taiwan University Hospital

Completed

Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) (ALPHA)

Head and Neck Neoplasms

Taiwan
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (TAPIS)

HNSCC

France
Samsung Medical Center
AstraZeneca

Unknown

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

EGFR Mutation Positive Non-small Cell Lung Cancer

Korea, Republic of
Boehringer Ingelheim

Completed

Afatinib in NSCLC With HER2 Mutation

Carcinoma, Non-Small-Cell Lung

Malaysia, China
Boehringer Ingelheim

Completed

Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects

Healthy

Germany
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Boehringer Ingelheim

Completed

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Breast Neoplasms | Neoplasm Metastasis

United States, Canada, Finland, France, Germany, Italy, Korea, Republic of, Spain

Search clinical trials for: bafetinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations